The University of Nevada, Reno School of Medicine

Is Easi 75 Good Enough or Can We Do Better Elevating Efficacy and Long-term Safety with Jak Inhibitors in Moderate-to-Severe (1080p)

MD, PhD

DO, MPH

thumbnail_Is EASI 75 Good Enough or Can We Do Better_383x158.png

Is EASI 75 Good Enough or Can We Do Better_383x158.png

Discuss optimization of treatment selection based on head-to-head data on systemic Janus kinase (JAK) inhibitors in moderate-to-severe atopic dermatitis 

Review long-term benefit-risk profile for systemic JAK inhibitors for the treatment of moderate-to-severe AD

Identify strategies to employ new efficacy targets in the treat-to-target framework for the management of moderate-to-severe atopic dermatitis 

Describe shared decision-making approaches for managing moderate-to-severe atopic dermatitis with systemic JAK inhibitors 

thumbnail_Is EASI 75 Good Enough or Can We Do Better.png

Is EASI 75 Good Enough or Can We Do Better.png

Atopic Dermatitis

On-Demand CME Videos

FC24: Is EASI 75 Good Enough or Can We Do Better? Elevating Efficacy and Long-Term Safety With JAK Inhibitors in Moderate-to-Severe Atopic Dermatitis: An Online Activity

FC24: Is EASI 75 Good Enough or Can We Do Better? Elevating Efficacy and Long-Term Safety With JAK Inhibitors in Moderate-to-Severe Atopic Dermatitis: An Online Activity

About

Availability

Learning Objectives

Intended Audience

Faculty

Accreditation Statement

Credit Designation Statement

Disclosures